Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Total Current Liabilities (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Total Current Liabilities for 8 consecutive years, with $23.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities fell 19.66% year-over-year to $23.5 million, compared with a TTM value of $23.5 million through Sep 2025, down 19.66%, and an annual FY2024 reading of $32.9 million, up 43.81% over the prior year.
  • Total Current Liabilities was $23.5 million for Q3 2025 at X4 Pharmaceuticals, up from $22.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $32.9 million in Q4 2024 and bottomed at $13.1 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $22.1 million, with a median of $22.9 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities skyrocketed 117.0% in 2022, then fell 20.78% in 2025.
  • Year by year, Total Current Liabilities stood at $14.0 million in 2021, then soared by 59.2% to $22.3 million in 2022, then increased by 2.41% to $22.9 million in 2023, then soared by 43.81% to $32.9 million in 2024, then decreased by 28.5% to $23.5 million in 2025.
  • Business Quant data shows Total Current Liabilities for XFOR at $23.5 million in Q3 2025, $22.9 million in Q2 2025, and $25.9 million in Q1 2025.